Zhejiang Dayang Biotech Group (003017.SZ) shareholder Wang Xiangao plans to reduce his holdings by no more than 570,000 shares.

20:09 17/12/2025

Da Yang Biological (003017.SZ) announced that shareholder Wang Xianguo, who holds more than 5% of the company's shares, plans to reduce his holdings through centralized bidding trading within 3 months from the date of the pre-disclosure announcement of the share reduction plan, starting 15 trading days after that day (from January 12, 2026 to April 11, 2026, excluding the period when reducing holdings is prohibited according to the regulations of the China Securities Regulatory Commission or the Shenzhen Stock Exchange), reducing a total of no more than 570,000 shares (including this amount), not exceeding 0.68% of the total number of company shares.

Zhejiang Dayang Biotech Group (003017.SZ) issued an announcement that the shareholder Wang Xianguo, who holds more than 5% of the company's shares, plans to reduce his holdings by a total of no more than 570,000 shares (including this amount) through centralized bidding trading within 3 months after 15 trading days from the date of disclosure of this share reduction plan (from January 12, 2026 to April 11, 2026, excluding the period prohibited from reduction according to relevant regulations of the China Securities Regulatory Commission or Shenzhen Stock Exchange), not exceeding 0.68% of the total company's shares.

LIANLIAN (02598) spent HKD 996,500 on December 17 to repurchase 158,500 shares.

Nebius (NBIS.US) launches the new generation AI cloud platform powered by NVIDIA Corporation's Blackwell Ultra chip to compete with CoreWeave.

BIOSTAR PHARM-B(02563): Yutidelong treatment of brain metastases in breast cancer, the first patient in the United States treated with key clinical research.

LIANLIAN (02598) spent HKD 996,500 on December 17 to repurchase 158,500 shares.

Nebius (NBIS.US) launches the new generation AI cloud platform powered by NVIDIA Corporation's Blackwell Ultra chip to compete with CoreWeave.

BIOSTAR PHARM-B(02563): Yutidelong treatment of brain metastases in breast cancer, the first patient in the United States treated with key clinical research.